Introduction
Recent advancements in artificial intelligence are transforming breast cancer treatment, providing clinicians with valuable tools to enhance patient care. One such innovation is ArteraAI Breast, a digital pathology-based risk stratification tool now authorized by the FDA for early-stage hormone receptor-positive, HER2-negative invasive breast cancer.
The FDA has granted approval for ArteraAI Breast, a digital pathology-based risk stratification tool aimed at early-stage, hormone receptor (HR)–positive, HER2-negative invasive breast cancer patients, according to a press release from its developer, Artera.1
ArteraAI Breast utilizes artificial intelligence to produce risk scores that provide prognostic insights regarding the likelihood of distant metastasis in early-stage breast cancer patients. The tool analyzes digitized histopathology images alongside patient clinical data, stratifying individuals into low- and high-risk categories based on a defined risk score threshold. By delivering pathology-based risk evaluations around the time of diagnosis, this platform aids clinicians in contextualizing risks within established clinical frameworks.
Eric Winer, MD, a medical oncologist and director of the Yale Cancer Center, emphasized, “This clearance represents an essential step toward personalizing treatments for patients with early-stage breast cancer. The integration of AI and digital pathology has the potential to enhance operational efficiencies while fostering a stronger interdisciplinary connection between oncology and pathology. This approach may further improve clinicians’ ability to assist patients in making informed treatment decisions.”
The multimodal artificial intelligence (MMAI) platform employs a distinctive algorithm that integrates both digital images from a patient’s resection alongside their clinical data.2 The algorithm is built on a substantial dataset comprising thousands of patients and tens of thousands of pathology slides, validated through various phase 3 trial results across different patient groups.
In a review of 9 phase 3 breast cancer trials, ArteraAI demonstrated its prognostic capabilities in predicting distant metastasis risks in patients with HR-positive early-stage breast cancer, thereby aiding clinicians in decision-making for treatment. Developers noted that test outcomes could be reported within 1 to 2 days after collecting samples from a patient’s resection, all while eliminating the risk of inconclusive results due to inadequate tissue samples. Moreover, the test showed strong independent prognostic and predictive performance for chemotherapy benefits in the NSABP B-20 trial. Patients identified as MMAI low showed no advantage from additional chemotherapy, while those classified as MMAI high saw substantial benefits.
The developers previously shared findings highlighting the prognostic and predictive utility of their MMAI model at the
In another discussion, analyzing postmenopausal patients in the ABCSG 8 trial (NCT00291759), the MMAI platform successfully categorized patients into low-, intermediate-, and high-risk groups, revealing 10-year distant metastasis-free survival rates of approximately 95%, 89%, and 77%, respectively. Additionally, findings concerning patients with node-negative, HR-positive disease in the NSABP B-20 trial indicated that individuals identified as MMAI high risk experienced a 52% relative reduction in 10-year distant metastasis rates associated with chemotherapy.
Andre Esteva, chief executive officer and co-founder of Artera, stated, “FDA clearance for ArteraAI Breast signifies a considerable expansion of our FDA-cleared AI platform in oncology. This achievement reflects our technology’s increasing significance across various cancer types. Breast cancer management is intricately nuanced, and treatment choices hinge on personalized risk. Our objective remains consistent across different cancers, including prostate and breast: to empower clinicians to convert complex data into more accurate and tailored treatment approaches throughout the patient’s cancer journey.”1
References
- Artera receives U.S. FDA clearance for ArteraAI Breast, expanding its AI platform to breast cancer. News release. Artera. May 6, 2026. Accessed May 6, 2026. https://tinyurl.com/w6u8vv6c
- Rethink what’s possible in breast cancer testing. Artera. Accessed May 6, 2026. https://tinyurl.com/4r9hb2xt
- Artera unveils data demonstrating prognostic and predictive utility in breast cancer at SABCS 2025. News release. Artera. November 24, 2025. Accessed May 6, 2026. https://tinyurl.com/4c9hk66x
